An observational study in Aortic Regurgitation, Mitral Regurgitation and Aortic Stenosis, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by The Cleveland Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Aortic Valve Insufficiency with a site in United States — 7 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · United States.
Among the 41 studies in Aortic Valve Insufficiency with a site in United States, this one is the 7th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2024, is one of 17 observational ones, reaches primary completion later than 15 of the 16 other live ones, and was the 39th registered.
170 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.
Browse Aortic Valve Insufficiency studies →7 of the 41 studies in Aortic Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18+
JenaValve Technology, Inc. · Sites in United States
Edwards Lifesciences · Sites in United States, Canada
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in United States, Canada
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 200 is below the median of 229 across 76 observational studies indexed under Aortic Valve Insufficiency.
Median enrollment 226 across the 24 interventional studies, 200 across the 17 observational. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 41 have an industry lead sponsor. The 10 most frequent:
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
The Cleveland Clinic has 5 studies filed under Aortic Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Aortic Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06608823JenaValve Technology, Inc.ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | 2027-06 |
| NCT04149600Beth Israel Deaconess Medical CenterIdentification of Genetic Causes of Calcific Aortic Valve Disease | 2027-06-30 |
| NCT05459233Institut universitaire de cardiologie et de pneumologie de Québec, University LavalValve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR | 2027-09-01 |
| NCT07197736Columbia UniversityDELINEATE-Prospective | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Aortic Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims to validate sex-specific biologic signatures associated with aortic valve disease developed in a large multicenter CMR registry, using unsupervised phenomapping.
The aim to use standard and advanced CMR techniques (MRF, DTI, chemical exchange transfer, and radiomics analysis) is to determine advanced CMR predictors of reverse remodeling following aortic valve surgery and develop sex-specific thresholds for risk. Infrastructure developed by this study will enable development of an innovative, scalable, sex-specific precision medicine cardiovascular imaging pipeline to determine overall risk and treatment response.
Chronic valvular heart disease leads to significant left ventricular (LV) remodeling. Current national guidelines for surgical/procedural referral for valvular heart disease do not consider sex differences in presence of symptoms, LV remodeling and dysfunction. However, our prior research in patients with chronic aortic regurgitation, validated by our recent multicenter study, demonstrated that despite higher left ventricular function, and less ventricular dilation, females experienced more heart failure symptoms, fewer referrals for surgical intervention, and higher prevalence of adverse outcomes compared to males. Similarly, published HVTI data have demonstrated increased adverse outcomes in women referred for surgical mitral valve intervention.
Cardiac magnetic resonance (CMR) provides an exciting opportunity to characterize sex differences in LV remodeling.In combination with conventional CMR measures, novel CMR techniques such as Magnetic Resonance Fingerprinting (MRF), Diffusion Tensor imaging (DTI) and radiomics analysis provide tissue level specificity with potential to enhance phenomapping.
Limitations in understanding sex-specific remodeling patterns stem from heterogeneity of presentation, which confound traditional analytic methods. Phenomapping, a method of machine learning, clusters imaging features and patients into distinct phenotypic groups. Unsupervised phenomapping enables unbiased grouping of patients by both clinical characteristics as well as complex imaging features. In recent studies, this unbiased phenomapping approach demonstrates superior risk stratification of cardiac disease compared to traditional approaches that can be used to guide individualized treatment
The aim to use advanced CMR techniques (MRF, DTI, chemical exchange transfer, and radiomics analysis) is to determine advanced CMR predictors of reverse remodeling following procedural valve intervention and develop sex-specific thresholds for risk. Results from this study would enable the development of sex-specific precision medicine pathway, augmented by advanced imaging features, to better predict overall risk and treatment response, and thus enable novel patient selection criteria.
Study hypothesis: Radiomics, MRF, chemical exchange transfer, and DTI will elucidate distinct sex-specific biologic signatures, in addition to standard CMR imaging features, and are associated with adverse outcomes, and reverse remodeling following surgical/procedural valve intervention.
Patients with at least moderate Aortic Stenosis or Aortic Regurgitation who are scheduled for a surgical repair or replacement of their aortic valve.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any to cardiac MRI including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cardiac MRI (CMR) with Magnetic Resonance Fingerprinting (MRF), fSENC (a new CMR technology which may detect subclinical signs of myocardial damage by measuring myocardial strain), Diffusion Tensor imaging (DTI), and chemical exchange transfer imaging with contrast at baseline and without contrast at follow up. Rapid Assessment of Physical Activity questionnaire Kansas City Cardiomyopathy Questionnaire
Diagnostic Test: CMR · Other: Quality of Life Questionnaire
CMR (with contrast at baseline and non-contrast at follow-up)
Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire
Change in LV Dilation and/or change in LVEF
Significant change in LV remodeling will be defined as a change in EF by 10 units (reverse remodeling is defined at least 10 unit decrease) or change in LV end-diastolic/systolic volume by 10% (Reverse remodeling is defined as at least decrease in LV end-diastolic/systolic volume by 10%
Time frame: 6-12 months
Change in Aortic Regurgiation
Change in Aortic Regurgitant Fraction will be modeled as a continuous variable, as well as a threshold change of 5 points or more, as measured by cardiac MRI
Time frame: 6-12 months
Change in BNP
NT-proBNP will be modeled as a continuous variable as well as a threshold change of 30% or decrease to level \< 1000
Time frame: 6-12 months
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score
KCCQ will be modeled as a continuous variable, as well as a threshold change of 5 points or more. KCCQ scoring transforms Likert-scale answers into 0-100 scores (higher is better) for domains like Physical Limitation, Symptom Frequency, Quality of Life, and Social Limitations, with a summary score reflecting overall health, where 0-24 is very poor, 25-49 poor/fair, 50-74 fair/good, and 75-100 good/excellent health.
Time frame: 6-12 months
6 minute walk test
6 minute walk test will be modeled as a continuous variable as well as a threshold change of 30meters or more
Time frame: 6-12 months
Started Dec 2024 (actual). Primary completion is estimated for Dec 2030, 72 months after the start.
Of 35 observational studies under Aortic Valve Insufficiency, half reached primary completion within 86 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 132. This study's planned 72 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.